Your browser is no longer supported. Please, upgrade your browser.
Sage Therapeutics, Inc.
Index- P/E8.52 EPS (ttm)10.25 Insider Own0.20% Shs Outstand52.12M Perf Week7.63%
Market Cap5.00B Forward P/E- EPS next Y-5.92 Insider Trans0.00% Shs Float51.11M Perf Month10.10%
Income606.10M PEG0.19 EPS next Q-0.77 Inst Own93.80% Short Float9.98% Perf Quarter5.54%
Sales1.11B P/S4.49 EPS this Y185.50% Inst Trans0.58% Short Ratio9.04 Perf Half Y87.42%
Book/sh39.76 P/B2.20 EPS next Y-29.20% ROA51.90% Target Price102.00 Perf Year85.70%
Cash/sh36.63 P/C2.38 EPS next 5Y43.80% ROE56.10% 52W Range25.01 - 98.39 Perf YTD0.89%
Dividend- P/FCF7.53 EPS past 5Y39.90% ROI28.80% 52W High-13.04% Beta2.04
Dividend %- Quick Ratio31.60 Sales past 5Y- Gross Margin99.90% 52W Low242.10% ATR4.84
Employees675 Current Ratio31.60 Sales Q/Q56491.10% Oper. Margin53.50% RSI (14)53.42 Volatility7.18% 5.43%
OptionableYes Debt/Eq0.00 EPS Q/Q633.30% Profit Margin54.40% Rel Volume0.78 Prev Close87.28
ShortableYes LT Debt/Eq0.00 EarningsFeb 24 BMO Payout0.00% Avg Volume564.37K Price85.56
Recom1.90 SMA203.88% SMA500.33% SMA20036.37% Volume203,342 Change-1.97%
Feb-26-21Downgrade Mizuho Buy → Neutral $81
Feb-25-21Reiterated H.C. Wainwright Neutral $74 → $86
Feb-02-21Resumed Raymond James Mkt Perform
Jan-22-21Downgrade BMO Capital Markets Outperform → Market Perform $95
Jan-04-21Upgrade Guggenheim Neutral → Buy
Jan-04-21Downgrade RBC Capital Mkts Outperform → Sector Perform $83 → $86
Dec-04-20Upgrade Mizuho Neutral → Buy $77 → $81
Dec-01-20Downgrade Raymond James Outperform → Mkt Perform
Nov-16-20Downgrade Morgan Stanley Overweight → Equal-Weight $87 → $85
Nov-06-20Reiterated H.C. Wainwright Neutral $76 → $81
Sep-11-20Upgrade Wedbush Neutral → Outperform
Aug-10-20Upgrade Raymond James Mkt Perform → Outperform $70
May-08-20Downgrade Wedbush Outperform → Neutral
Apr-08-20Downgrade Guggenheim Buy → Neutral
Mar-18-20Upgrade RBC Capital Mkts Sector Perform → Outperform $73 → $60
Mar-06-20Initiated Citigroup Buy $71
Feb-28-20Reiterated H.C. Wainwright Neutral $87 → $78
Feb-06-20Initiated Mizuho Neutral
Dec-06-19Reiterated RBC Capital Mkts Outperform $190 → $100
Dec-05-19Reiterated Guggenheim Buy $200 → $110
Feb-26-21 12:00AM  
Feb-25-21 07:09AM  
Feb-24-21 06:53AM  
Feb-11-21 05:00PM  
Feb-10-21 06:30AM  
Feb-07-21 01:44PM  
Jan-07-21 06:30AM  
Jan-04-21 10:04AM  
Dec-23-20 06:30AM  
Dec-22-20 09:39AM  
Dec-20-20 04:00AM  
Dec-19-20 07:46AM  
Dec-18-20 06:45AM  
Dec-16-20 06:30AM  
Dec-12-20 07:20AM  
Dec-09-20 07:54AM  
Dec-04-20 09:32AM  
Dec-03-20 04:30PM  
Dec-02-20 12:56PM  
Dec-01-20 11:55AM  
Nov-30-20 10:42AM  
Nov-29-20 09:32AM  
Nov-27-20 01:18PM  
Nov-18-20 12:04AM  
Nov-09-20 08:26AM  
Nov-05-20 09:31PM  
Nov-02-20 06:30AM  
Oct-22-20 06:30AM  
Oct-21-20 11:09AM  
Oct-19-20 05:00PM  
Oct-15-20 06:30AM  
Oct-01-20 07:00AM  
Sep-16-20 04:55PM  
Sep-15-20 09:56AM  
Sep-11-20 01:38PM  
Sep-10-20 06:30AM  
Sep-01-20 06:30AM  
Aug-20-20 04:31PM  
Aug-10-20 05:31PM  
Jul-30-20 06:30AM  
Jul-21-20 06:30AM  
Jul-13-20 10:22AM  
Jun-24-20 03:58PM  
Jun-17-20 04:04PM  
Jun-10-20 08:37PM  
Jun-09-20 09:55AM  
Jun-01-20 06:30AM  
May-09-20 05:01PM  
May-08-20 06:30AM  
May-07-20 04:01PM  
May-03-20 07:30PM  
Apr-22-20 11:09AM  
Apr-21-20 07:39AM  
Apr-20-20 07:48AM  
Apr-16-20 06:30AM  
Apr-13-20 10:51AM  
Apr-08-20 12:29PM  
Apr-07-20 04:01PM  
Apr-03-20 04:30PM  
Mar-27-20 02:53PM  
Mar-20-20 08:30PM  
Mar-19-20 06:57PM  
Mar-18-20 06:30AM  
Mar-12-20 08:45AM  
Mar-11-20 07:00AM  
Mar-04-20 04:30PM  
Mar-02-20 09:59AM  
Feb-27-20 07:39PM  
Feb-26-20 08:31AM  
Feb-25-20 12:03PM  
Feb-24-20 06:30AM  
Feb-10-20 06:30AM  
Feb-04-20 04:30PM  
Feb-03-20 11:27AM  
Jan-17-20 08:40AM  
Jan-09-20 08:44AM  
Jan-03-20 04:30PM  
Dec-29-19 03:24AM  
Dec-23-19 02:47PM  
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company's product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson's diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington's disease, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217; Biogen Inc. to develop and commercialize zuranolone (SAGE-217) for various depressive disorder, postpartum depression, and other psychiatric disorders, as well as SAGE-324 for essential tremor and other neurological disorders; and Biogen MA Inc. and Biogen International GmbH for the development, manufacture, and commercialization of products containing SAGE-217 molecule and products containing the SAGE-324 molecule. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JONAS JEFFREY MChief Innovation OfficerJan 27Option Exercise0.451,80081056,330Jan 28 04:02 PM
IGUCHI KIMICFO & TreasurerJan 05Option Exercise1.361,7502,38035,355Jan 06 04:23 PM
IGUCHI KIMICFO & TreasurerApr 30Option Exercise1.364,0005,44033,261May 04 04:53 PM